Xentria

Xentria, Inc. is a clinical-stage biotherapeutics company founded in 2020 and headquartered in Chicago. The company focuses on developing novel biologics to address unmet clinical needs, particularly for rare diseases, immunologic disorders, and oncological conditions. Xentria's lead candidate is XTMAB-16, an anti-TNFα monoclonal antibody being developed for the treatment of pulmonary sarcoidosis, a chronic inflammatory disorder primarily affecting the lungs. XTMAB-16 has shown promise in preclinical studies to potentially reduce the formation of sarcoidosis granulomas, the key inflammatory feature of the disease. In 2022, Xentria completed a Phase I clinical trial of XTMAB-16 in healthy volunteers. As of November 2023, the company had enrolled the first US patient in a global Phase Ib/IIa clinical study to evaluate XTMAB-16 for pulmonary sarcoidosis treatment. XTMAB-16 has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of sarcoidosis.

Key customers and partnerships

In June 2023, Xentria entered into an exclusive multi-year licensing agreement with Meitheal Pharmaceuticals for the marketing of XTMAB-16 in North America. Under this agreement, Meitheal obtained sole rights to commercialize the biologic in North America, while Xentria retained marketing rights in all other regions. Xentria received an upfront payment of USD 45 million and is eligible for up to USD 35 million on regulatory submission and approval, as well as potential milestone-based royalty payments exceeding USD 600 million.